Breaking news

EU Commits €4.7 Billion To Renewable Energy and Vaccine Production In South Africa

by News Editor
In a landmark move, the European Union is set to inject nearly €5 billion into South Africa’s renewable energy transition and vaccine production efforts. The announcement, made by the European Commission, highlights the EU’s commitment to strengthening its ties with the African continent’s most developed economy.

Key Details Of The Investment

  • First of Its Kind: South Africa stands out as the first nation to forge such a comprehensive agreement with the EU.
  • Breakdown of Funds: A substantial €4.4 billion is earmarked for clean energy projects, while €700 million will bolster vaccine production, aiming to fortify public health infrastructure.
  • Strengthening Partnerships: Leaders, including Ursula von der Leyen and Cyril Ramaphosa, are focusing on expanding cooperation in critical raw materials, reflecting a growing alliance.

Such initiatives align with global trends in renewable energy and digital infrastructure advancements.

Read more about sustainable practices in tech and other insightful pieces on The Future Media.

As the EU and South Africa embark on this transformative journey, the global community watches closely.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

by News Editor

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

eCredo
Aretilaw firm
The Future Forbes Realty Global Properties
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter